ERBB2 and neoplasm: As shown in Figure 1c, though slightly inferior shift extent compared with trastuzumab, T-SA1 and T-SA2 could specifically bind to HER2-positive cells instead of MCF-7 cell with low expression of HER2, indicating that anti-HER2 scFv–HSA fusion antibodies have good binding activity to HER2-positive tumor cells.